Ask AI

Rethinking MZL: From Established Options to T-Cell–Directed Therapies

Podcast
This activity is available for 0.50 CME/CE credit(s).

Released: November 04, 2026

Expiration: May 03, 2027

See Activity Collection

This podcast explores the evolving treatment landscape for marginal zone lymphoma (MZL), focusing on individualized treatment selection, emerging cellular therapies, and novel T-cell–engaging approaches for relapsed/refractory disease. Examine evidence supporting current treatment options, including BTK inhibitors and CAR T-cell therapy, as well as emerging clinical data on CD20 x CD3 bispecific antibodies such as odronextamab and mosunetuzumab. The discussion also addresses clinical trial referral, patient eligibility, and practical strategies for monitoring and managing treatment-related toxicities, including cytokine release syndrome, infections, and hypogammaglobulinemia.

Rethinking MZL Therapy

Pre Assessment

Assess your current knowledge and clinical approach before beginning your podcast.
1.

How many people with MZL do you provide care for in a typical month?​

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

What was the approximate response rate reported for odronextamab, a bispecific antibody in the phase II ELM-2 trial for patients with relapsed/refractory MZL?

4.

You are counseling your team about implementing bispecific antibodies at your clinic. What should you tell them about the incidence rate of cytokine release syndrome associated with bispecific antibody treatment in patients with MZL compared with patients with FL?